Clinical Pre-screening Protocol for Ovarian Cancer
ConditionOvarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAllarity Therapeutics
About this trial
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Eligibility criteria
Qualifiers
Patients with histological confirmed epithelia ovarian cancer
Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
FFPE tumor tissue available
Disqualifiers
Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Trial design
Treatments tested in this trial
- Drug Response Predictor® (DRP)
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Allarity Therapeutics
Lead sponsor
Amarex Clinical Research
Collaborator
Source ClinicalTrials.gov